Business Wire

Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation

Share

Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition due to progressive severe liver dysfunction, accompanied by jaundice, portal hypertension, hepatosplenomegaly and failure to thrive. The symptoms of the disease usually appear first in childhood with progressive cholestasis, evolving to hepatic failure, cirrhosis and need for liver transplantation.

We are very pleased to receive these designations which further validate Vivet’s efforts to treat rare inherited metabolic disorders. The FDA and EC have both recognized the unmet need for a safe and effective treatment of PFIC3 and the potential of VTX-803 to address such need. The field of Progressive Familial Intrahepatic Cholestasis has been gaining increased attention in the medical field with numerous ongoing clinical trials. There is a high unmet medical need, especially in the paediatric segment, for this condition, for which liver transplantation remains the only truly curative option today” stated Jean-Philippe Combal, co-founder & CEO of Vivet Therapeutics.

VTX-803 is Vivet’s second gene therapy product to be granted Orphan Drug Designation. This is an important value driver for Vivet which would provide 10 & 7 years of market exclusivity in the EU & US respectively if VTX-803 is approved for the treatment of PFIC3. VTX-803 is currently under IND-enabling studies and initiation of clinical development is planned for the second part of 2021 in both the US and the EU.

“We are very happy about this recognition of our scientific achievement for a complex liver disease and further validation of our strategic collaboration with Fundación para la Investigación Médica Aplicada (FIMA). This program could be a game-changer in the gene therapy field for PFIC disorders” added Dr. Gloria González-Aseguinolaza, Vivet Therapeutics co-founder & CSO and deputy director at CIMA.

VTX-803 was recently the subject of an oral presentation at 2019 ASGCT (American Society of Gene and Cell Therapy), a lecture at the 2019 ESGCT (European Society of Gene and Cell Therapy) annual meetings and a publication in Nature Communications (Weber et al. Nature Communications, 2019, 10(1):5694).

About Vivet Therapeutics
Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada, University of Navarra based in Pamplona, Spain.

Vivet’s lead program, VTX-801, is a novel investigational gene therapy for Wilson disease which has been granted Orphan Drug Designation by the Food and Drug Administration and the European Commission.

Contact information

Media & Investor:
Thomas Daniel
Business Development Director
+33 182283082
info@vivet-therapeutics.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMI to Address Equality & Transformation During Upcoming International Events29.9.2020 16:22:00 CESTPress release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced its participation in several global forums focused on equality in the workplace. Members of PMI’s Senior Management Team—including Chief Diversity Officer Silke Muenster—will detail the steps PMI is taking to further diversify its workplace and explain how fostering a culture built on broader perspectives increases creativity and productivity, ultimately driving innovation and consumer-centricity. Events include: - Sept. 30: Marian Salzman, senior vice president, global communications, will address The Hill’shttps://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthehill.com%2Fevent%2F517572-century-of-the-woman&esheet=52297021&newsitemid=20200929005799&lan=en-US&anchor=%26%238220%3BCentury+of+the+Woman%2C%26%238221%3B&index=2&md5=dd59f1acaf064094c36e98292381df3c “Century of the Woman,” anevent bringing together remarkable women leaders and decision-makers to discuss progress toward equality and the barriers th

SMITHS DETECTION INTRODUCES COMPACT X-RAY SCANNER FOR VERSATILE COMMERCIAL SECURITY APPLICATIONS29.9.2020 16:00:00 CESTPress release

Smiths Detection announces its newest X-ray inspection system, HI-SCAN 5030C, that addresses a critical gap in commercial security screening solutions with its optimal size, durability and mobility. Combined with a market-leading HiTraX 3 electronic platform for superior image quality, the HI-SCAN 5030C is specifically designed to enhance security screening operations from courthouses to corporate campuses. Its compact size and lightweight construction enable it to fit seamlessly into checkpoints and mailrooms. Vibration absorbers make it possible to transport HI-SCAN 5030C between various locations without requiring re-calibration, providing maximum flexibility. The HI-SCAN 5030C is Smiths Detection’s smallest X-ray inspection system and offers a wide variety of options including stainless steel castors, storage compartment, 24” monitor, newly designed keyboard with image manipulation keys, and foldable input/output conveyors. It can be upgraded with add-on software packages for train

Andersen Global Strengthens Caribbean Presence with Addition of Templar Chambers29.9.2020 15:30:00 CESTPress release

Andersen Global enters a Collaboration Agreement with Templar Chambers, one of the largest law firms in Guyana, providing additional coverage for the organization’s Caribbean platform. The full-service law firm was founded in 2004 and provides legal expertise across a wide spectrum of practice areas including banking and finance, corporate, contract and commercial, energy, mining, oil and gas, real estate, litigation as well as intellectual property. The firm brings in a highly experienced team of four attorneys and seven staff members, providing services to local and international clients doing business in Guyana. “Our firm is proud of the key role that we play in supporting Guyana’s development by helping new business enterprises grow and international companies enter the Guyanese market,” Office Managing Partner Glenn Hanoman said. “As one of Guyana’s leading commercial and business law firms, we are committed to providing our clients with best-in-class solutions. Our values and vis

Airship’s Data Study of Nearly 750 Million Individual App Users Finds Mobile App Engagement Rates Have Soared Under Lockdown29.9.2020 15:00:00 CESTPress release

Customer engagement company Airship today revealed top-level results of its global benchmark study, examining the state of mobile app behaviors across nearly 750 million people worldwide. To distinguish between the impact of the pandemic and longer-term changes due to growing data regulations, more stringent app review policies by Apple and Google and ongoing evolution in user behavior, February 2020 was used for year-over-year analysis and then compared to March-June 2020. The full report is available for download here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005324/en/ From February 2019 to February 2020, all regions saw average direct app opens (when a user opens an app from a click on a web or push notification) per user per month decline. March-June 2020 reversed this trend with all but one region seeing growth. (Graphic: Business Wire) Key findings show that the global pandemic led to massive gains for sev

Cat Rock Capital Issues Presentation on Just Eat Takeaway.com Merger with Grubhub29.9.2020 14:58:00 CESTPress release

Cat Rock Capital Management LP (together with its affiliates, “Cat Rock Capital”), a long-term oriented investment firm and beneficial owner of approximately 6.8 million shares of the common stock of Just Eat Takeaway.com NV (“Just Eat Takeaway.com”, “JET”, or the “Company”) (LSE: JET), representing circa 4.5% of Just Eat Takeaway.com’s outstanding shares, today released a public presentation on the Just Eat Takeaway.com offer for Grubhub Inc. (“Grubhub”). This presentation can be found at JustEatDoesDeliver.com and is also available upon request via info@catrockcap.com. Alex Captain, Founder and Managing Partner, Cat Rock Capital Management LP, commented: “Cat Rock has been a shareholder of Just Eat Takeaway.com NV (“JET” or “the Company”) and its predecessor companies for over three years, and our firm has intensively researched the global online food delivery sector for over five years. We have developed a great respect for CEO Jitse Groen, his team, and his strategy over that time.

Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker29.9.2020 14:00:00 CESTPress release

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH). The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongoing and will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101. “With the launch of this first-in-human trial, Inversago is now a clinical-stage company, and confirms its lead in the comeback of small molecule peripheral CB1 blockers”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “Dosing of our first patient with INV-101 represents an important milestone to accomplish the Company’s vision: offering a potentially meaningful the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom